RedHill Biopharma (RDHL) EBITDA (2012 - 2023)

RedHill Biopharma (RDHL) has 12 years of EBITDA data on file, last reported at $53.8 million in Q2 2023.

• EBITDA for Q2 2023 came in at $53.8 million, up 486.88% year-over-year; the trailing twelve-month figure through Jun 2023 was -$15.4 million (up 83.63% YoY), and the FY2025 annual result was -$7.9 million, down 34.91% from the prior year.
• EBITDA grew to $53.8 million in Q2 2023 per RDHL's latest filing, from -$29.1 million in the prior quarter.
• Over five years, EBITDA peaked at $53.8 million in Q2 2023 and troughed at -$141.6 million in Q4 2021.
• A 5-year average of $2.5 million and a median of $13.5 million in 2020 frame the typical range for EBITDA.
• The sharpest annual moves came in 2021 and 2023: EBITDA plunged 818.34% in 2021, then jumped 486.88% in 2023.
• A 5-year view of EBITDA shows it stood at $11.8 million in 2019, then surged by 67.53% to $19.7 million in 2020, then sank by 818.34% to -$141.6 million in 2021, then soared by 46.5% to -$75.7 million in 2022, then surged by 170.97% to $53.8 million in 2023.
• Business Quant data shows RDHL's EBITDA at $53.8 million in Q2 2023, -$29.1 million in Q1 2023, and -$75.7 million in Q4 2022.